Todd Daugherty, MD
Rheumatology · Henniker, NHNPI 1639390776
Payments from drug & device makers
Across 368 payments — averaging $58.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$9K
- Amgen$4K
- Janssen Global Services, LLC$2K
- UCB, Inc.$1K
- Janssen Scientific Affairs, LLC$1K
- AbbVie$956
- plus $4K from 22 others
What the payments were for
- Consulting fees$9,37043%
- Speaking & faculty fees$1,4006%
- Grants$2401%
- Food & beverage$10,05146%
- Education$6043%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 62 | $8,778 |
| Amgen(2 entities) | 53 | $3,745 |
| Janssen Global Services, LLC | 1 | $1,500 |
| UCB, Inc. | 60 | $1,337 |
| Janssen Scientific Affairs, LLC | 4 | $1,093 |
| AbbVie | 46 | $956 |
| Lilly USA, LLC | 28 | $600 |
| E.r. Squibb & Sons, L.L.C. | 14 | $534 |
| Mallinckrodt Hospital Products Inc. | 17 | $533 |
| Novartis | 6 | $480 |
| Pfizer | 16 | $375 |
| AstraZeneca | 13 | $281 |
| Sobi, Inc | 2 | $150 |
| Sanofi | 1 | $137 |
| ANI Pharmaceuticals, Inc. | 5 | $130 |
| Organon | 7 | $129 |
| GSK | 2 | $125 |
| Genentech, Inc. | 3 | $120 |
| Tersera Therapeutics LLC | 4 | $117 |
| Boehringer Ingelheim | 5 | $107 |
| Radius Health, Inc. | 4 | $93 |
| Invivyd Inc | 4 | $82 |
| Genentech USA, Inc. | 3 | $71 |
| Fresenius Kabi USA, LLC | 2 | $61 |
| Cardinal Health Inc | 2 | $56 |
| Sandoz | 2 | $32 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,665 in reported general payments places this provider in the 85th percentile of 48 rheumatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 13 | $87,331 |
| Humira(Cf) PenAdalimumab | 12 | $81,641 |
| Hydroxychloroquine Sulfate | 208 | $12,230 |
| Leflunomide | 116 | $10,915 |
| Sulfasalazine DrSulfasalazine | 69 | $7,605 |
| MethotrexateMethotrexate Sodium | 114 | $3,131 |
| Azathioprine | 18 | $927 |
| Sulfasalazine | 14 | $770 |
| Alendronate Sodium | 71 | $715 |
| Folic Acid | 27 | $523 |
| Prednisone | 42 | $451 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Henniker
- William RigbyLebanon$4.1M
- Jonathan KrantPeterborough$483K
- John GormanNashua$135K
- Robert SimmsLebanon$102K
- Naureen MirzaManchester$67K
- Christopher BurnsLebanon$59K
- Kalyani GovindarajuNashua$27K
- Stephanie MathewLebanon$10K
- Yan LiConcord$4K
- Jenny LinManchester$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.